-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Qw2bJrqIkxOqXq6Pd/xE/6TJe8mN2ieoqNX9Oxq39o28cr0jIWbYeIQjn3swiQOX
 66pqzwuZgUlKlHZbLwgStA==

<SEC-DOCUMENT>0001193125-08-100889.txt : 20080502
<SEC-HEADER>0001193125-08-100889.hdr.sgml : 20080502
<ACCEPTANCE-DATETIME>20080502170923
ACCESSION NUMBER:		0001193125-08-100889
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20080501
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080502
DATE AS OF CHANGE:		20080502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NUVELO INC
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		08799928

	BUSINESS ADDRESS:	
		STREET 1:		201 INDUSTRIAL ROAD
		STREET 2:		SUITE 310
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070-6211
		BUSINESS PHONE:		650-517-8000

	MAIL ADDRESS:	
		STREET 1:		201 INDUSTRIAL ROAD
		STREET 2:		SUITE 310
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070-6211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Date
of earliest event reported: May&nbsp;1, 2008 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>Nuvelo, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or Other Jurisdiction<BR>of Incorporation)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. Employer<BR>Identification No.)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>201 Industrial Road, Suite 310, San Carlos, CA 94070-6211 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>(650) 517-8000 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>N/A </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former Name or Former Address,
if Changed Since Last Report) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>ITEM&nbsp;3.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING </B></FONT></TD></TR></TABLE> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On May&nbsp;1, 2008, Nuvelo, Inc. (&#147;Nuvelo&#148; or the &#147;Company&#148;) received a staff deficiency letter from The Nasdaq Stock Market (&#147;Nasdaq&#148;)
indicating that, for the last 30 consecutive business days, the bid price for Nuvelo&#146;s common stock has closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Global Market under Marketplace Rule 4450(a)(5)
(the &#147;Rule&#148;). In accordance with Marketplace Rule&nbsp;4450(e)(2), Nuvelo was given 180 calendar days, or until October&nbsp;28, 2008, to regain compliance with the Rule. The letter also indicated that, if Nuvelo does not regain compliance
by October&nbsp;28, 2008, Nasdaq will provide written notification that Nuvelo&#146;s common stock will be delisted, after which Nuvelo may appeal the staff determination to the Nasdaq Listing Qualifications Panel. If Nuvelo does not regain
compliance with Marketplace Rule 4450(a)(5) by October&nbsp;28, 2008, but meets the Nasdaq Capital Market initial inclusion criteria set forth in Marketplace Rule 4310(c), except for the bid price requirement, it may apply to transfer the listing of
its securities to this market and, if accepted, be provided with an additional 180 calendar day compliance period to demonstrate compliance. If Nuvelo is not eligible for an additional compliance period at that time, Nasdaq Staff will provide
written notification that Nuvelo securities will be delisted. Upon such notice, Nuvelo may appeal the Nasdaq Staff&#146;s Determination to the Nasdaq Listing Qualifications Panel. There can be no assurance that, if Nuvelo does appeal the Nasdaq
Staff&#146;s Determination, that such appeal would be successful. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">A copy of the Company&#146;s press release announcing receipt of the staff determination
letter is attached hereto as Exhibit&nbsp;99.1 and is incorporated herein by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">(d)&nbsp;Exhibits. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:55pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>99.1</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Press Release titled &#147;Nuvelo Receives Nasdaq Notification,&#148; dated May 2, 2008.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Nuvelo, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman"
SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Lee Bendekgey</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Senior Vice President, Chief Financial Officer and General Counsel</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Dated: May&nbsp;2, 2008 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:55pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>99.1</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Press Release titled &#147;Nuvelo Receives Nasdaq Notification,&#148; dated May 2, 2008.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top">

<IMG SRC="g74711img.jpg" ALT="LOGO"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>PRESS RELEASE</B></FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Contact:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Danielle Bertrand</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">SVP, CFO and General Counsel</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">WeissComm Partners</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">415-946-1056</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">650-517-8358</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">dbertrand@wcpglobal.com</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">lbendekgey@nuvelo.com</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NUVELO RECEIVES NASDAQ NOTIFICATION </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">SAN CARLOS, Calif., May&nbsp;2, 2008 &#151; Nuvelo, Inc. (Nasdaq: NUVO) today announced that it received a staff deficiency letter from the Nasdaq Stock Market on
May&nbsp;1, 2008 indicating that, for the last 30 consecutive business days, the bid price of Nuvelo&#146;s common stock has closed below the minimum $1.00 per share requirement for continued listing under Marketplace Rule 4450(a)(5). </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The letter stated that under Marketplace Rule 4450(e)(2), Nuvelo will be provided with 180 calendar days, or until October&nbsp;28, 2008, to regain compliance with
Marketplace Rule 4450(a)(5). To regain compliance, the bid price of Nuvelo&#146;s common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days, anytime before October&nbsp;28, 2008. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">If Nuvelo does not regain compliance with Marketplace Rule 4450(a)(5) by October&nbsp;28, 2008, but meets The Nasdaq Capital Market initial inclusion criteria set forth
in Marketplace Rule 4310(c), except for the bid price requirement, it may apply to transfer the listing of its securities to this market and, if accepted, be provided with an additional 180 calendar day compliance period to demonstrate compliance.
If Nuvelo is not eligible for an additional compliance period at that time, Nasdaq Staff will provide written notification that Nuvelo securities will be delisted. Upon such notice, Nuvelo may appeal the Nasdaq Staff&#146;s Determination to the
Nasdaq Listing Qualifications Panel. There can be no assurance that, if Nuvelo does appeal the Nasdaq Staff&#146;s Determination, that such appeal would be successful. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>About Nuvelo </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and
commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo&#146;s development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential
short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition,
Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">201 Industrial Road, San Carlos, CA 94070&nbsp;&nbsp;&nbsp;&nbsp;tel:
650/517-8000&nbsp;&nbsp;&nbsp;&nbsp;fax: 650/517-8001&nbsp;&nbsp;&nbsp;&nbsp;www.nuvelo.com </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g74711img.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements,&#148; which include statements regarding Nuvelo&#146;s compliance
with Nasdaq listing requirements, potential proceedings to delist Nuvelo common stock from Nasdaq and the potential benefits that patients may experience from the use of our clinical stage compounds, which statements are hereby identified as
&#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management&#146;s current expectations and involve risks and uncertainties.
Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery and the regulatory approval process;
clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements;
stock market conditions; the impact of competitive products and technological changes; and uncertainties relating to our ability to obtain funding. These and other factors are identified and described in more detail in Nuvelo&#146;s filings with the
SEC, including without limitation Nuvelo&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2007 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"># # # </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">201 Industrial Road, San Carlos, CA 94070&nbsp;&nbsp;&nbsp;&nbsp;tel:
650/517-8000&nbsp;&nbsp;&nbsp;&nbsp;fax: 650/517-8001&nbsp;&nbsp;&nbsp;&nbsp;www.nuvelo.com </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g74711img.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g74711img.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!X17AI9@``24DJ``@````&`#$!`@`1
M````5@````$#!0`!````:`````,#`0`!`````NUP`Q!1`0`!`````0```!%1
M!``!````Q`X``!)1!``!````Q`X```````!-:6-R;W-O9G0@3V9F:6-E``"@
MA@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<
M'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-
M&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,O_``!$(`$P!#`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0``
M`````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%
M$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U
M-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MX>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#
M!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q
M$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?H
MZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/?J***`"BL7Q;K0T#PS>WX8"94V
MPY[R'A?\?PJOX+\2IXG\/Q71*BZC_=W"#LX[X]#U_P#U5'M(\_)U.E8.J\.\
M2E[B=OF=%7,>(/'VA^'@\<MS]HNEX^SP'<P/N>@_&N-^*FI>)M/N4CCNC%I$
MXPA@!4[NZNW7/?L"/H:\STFQ?5-9L[%<EKB98_S/)KBKXR49<D%J?2Y5PY2K
MT5BL14]RU[+]7^:_$^E]&OIM3T:TOIX1`]Q$)?+#9V@\@9^F*O5S_BW5G\->
M$;F\M`BR0JB0AAD9)`''TKB-)^,J':FKZ:5/>6V;(_[Y/^-=,J\*;4)O4\:C
ME6)QE.6(PT+QNU:^O?KON>KT5@:5XU\/:R52TU.'S3TCE/EM^38S^%;X((R#
MD5K&49*\7<\^K0JT9<M6+B_-6"BBBJ,@HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BD9E12S$`#J2<4H.1D=*`/'_C%K?F
M7=GHD3?+$//F`_O'A1^`R?Q%<GX&\3MX8\01S2$FSGQ'<*/[O9OJ.OYU]`76
MD:;>N7NM/M9V/5I858G\Q69-X(\,SDE]$LP3_<3;_+%<%3"U)5?:1D?68//<
M'2P*P56DVK:VMJWUZ?(T-4TRRU_2);*Z59;:=.&!Z=PRGU[UY;X*\&W>C_$B
M6&\3='91-+%+CY9`WRJ1^9^A%>M65G!I]G%:6J>7!$NU$R3M'IS4V!NW8&>F
M:Z9T8SE&3W1XV&S.KA:56A3=X336O3S^[?\`X!Y[\8;OR?"MM;@\SW0_)03_
M`(5XQ96-UJ-TEM9V\D\[_=2-<DU[OXU\(7?B[4-.A^T+;V%NKM*_5BQ(X`^@
MZFMK2-`T;PK8.+2&.W15S+/(?F8#NS'_`/57)6PTJU5MZ(][+L[HY=E\:<%S
M5'=VZ+72_P`NB_`X;PK\)HH"EWX@82OC(M$/R@_[1[_0<?6O3XHHX8DBB14C
M0!551@`#M7F.K_%N&/7;>WTV(/I\<P%Q.PYD7.#L'8=\]Z]/C=98UD1@R,`R
MD="#71A_8J\:?0\G./[0FX5<;IS;+M\NGY]QU5=3NSI^DWEZJ!S;P/*%)QNV
MJ3C]*M5F>)/^16U?_KRF_P#0#72>(>:>`/CE;>*]>72-5L(]-FGXM9%E+)(_
M]PY`P3V]>G7%>O5\4:'X.U#6_"NK:]IC,\NDR1M+"GWO+(8EU/JNW/TY[5]!
M?!SXG+XMTT:-JLH_MNU3AV/_`!](/XO]X=_S]<`'JM>9:;\4[F_^+<W@IM+B
M2&.66/[4)26.Q"V=N,<X]:]-KYTT!2G[5-V&&#]HN3^<+&@#Z+HK`\4>--!\
M&PVTNN7C6R7+,L1$3ON(QG[H..HK4TO4[36M+MM2L)#+:7,8DB<J5W*>AP>1
M0!;HK*\0^(]+\*Z4VIZQ<&"T5U0N(V?D].%!-4%\>>'F\('Q4MY(VCAMIG$#
MDCYMGW<;OO<=*`.DHK$\,^+=$\86,MYH=Y]IABD\MR8V0JV`>C`'H:VZ`"BN
M=A\<^'[CQ;)X7@O6DU>/.^%(7(7"[CEL;1@>_7CK6GK.MZ;X?TV34-5O(K2U
MCZR2'J?0#J3["@"_17D5Q^T1X2BG=(;/5)XU/^M6)0#[X+9_.NR\)?$7PUXT
MW)I-[_I2@EK6==DH'KCN/H30!;\;^(Y/"7A"_P!;BMEN7M54B)FVALL%Z_C6
M9\-/&\WCWPY-JD]E'9M'<M!Y:2%P0%4YR0/[U5_C+_R2C7/]R/\`]&+7.?LZ
M_P#)/[S_`+"#_P#H"4`>O450UC6]-\/Z;)J&JWD5I:Q]9)#C)]`.I/L.:\TG
M_:#\+K)(+;3]6N84ZS)`H4_FV1^-`'K5%<EX1^)'AKQJ3%I=X5NU&YK6==DF
M/4#HP^A-=%J>IV>CV$E]?S>3;1XWOM+8R<=`":`+=%<U'\0?"LMO).NLP"..
MW^U,65E_=;@N_!&2,D#BNCCD66-9$;<C@,I'<&@"*]M(;^RGL[A=T,Z-&X]B
M,5\Z7USKOA/6KK3HM3NX6MY"HV2L`R]CCIR,&OI*N`\=^`9O$^KV-Y921PM@
MQ7+OV4<@X[GJ/RKCQ=*4XJ4-T?1<.YA2PU65+$6]G)==DU_5ON.)T#Q]XTN[
MV*QLW74)7/$<D()QZDC&![DU[9IYO38Q'41`+LKF009V`^@SS6;X?\-:5X4T
M\QVB*IVYFN)"-SX[D]A[=*ATWQCINL^(9-)TTM<^3$9);A?N#!`P/[W7KTJJ
M,94DE4E=LRS.O2QTY2P=%1A'5M*WW]%Y+<Z&BBD9E52S$`#J2:ZCPC.UO7M.
M\/6+7>HW"QI_"@Y9SZ*.YKPGQ=XZU'Q3,8LFWT]6^2W4]?0L>Y_05[]=6%CJ
M486[M;>Z3L)4#C]:YV^^&WA:]R?[.$#'^*!RGZ=/TKDQ-*K45HO0^AR3'X#!
M2YZ\&Y]]&EZ+3[SYYKW;X5Z__:OAO[!,^;FP(3D\F,_=/X<C\!69??!BQ?<;
M#59XCV69`X_,8I/"_@+Q!X2\20WL-Q:W-HX\NX56*L4/?!'4<'KVKEP]&M1J
M)M:'O9MF.79E@Y0A4M-:JZ:U73MJM-SU"LSQ)_R*VK_]>4W_`*`:TZS/$G_(
MK:O_`->4W_H!KU3X`\:_9I`.G^(@>1YL'\GK#^*_P_N_`VNQ^,O#):"S\\2,
ML0_X])<]1_L$_@,XZ$5N?LT_\>'B+_KK!_)Z]RN[2WOK2:TNX4FMYD*21N,J
MRGJ"*`.0^&WQ`M/'N@"?Y(=2M\)=VX/0]G7_`&3^G(KRS1?^3K+K_KM/_P"D
MYK!\4Z!K'P5\=V^M:*[OI<SDP,V=K*?O02?AT/?`(Y'%WP-K5MXC_:-36+,.
ML%V9I%5Q@K_HYR#]#D4`=)^TM_R"O#__`%WF_P#05KTKX9?\DS\._P#7C'_*
MO-?VEO\`D%>'_P#KO-_Z"M>E?#+_`))GX=_Z\8_Y4`<W\??^27S_`/7W#_,T
MSX1:9;ZS\$+?3+M=UO="YAD'LTCC\Z?\??\`DE\__7W#_,U9^!G_`"2?2_\`
MKI/_`.C6H`\O^$%_<>!OBMJ'A/4'"I=.UL2>AE3)C8?[P)'_``(5]`>)]=@\
M,^&=0UFXP4M(2X4_Q-T5?Q)`_&O$/C_X?FTG7M*\9:>#&[NL4SKP5E3YHV^I
M`(_X#1\3/&+^/M-\)>&]%(:?5Q'<W"*<[&/RA#]&WD_[H-`&[\!-`N);?5/&
M>I`O>:I*RQ.PY*[LNWXMQ_P&N.\17,_Q7^-2:%)<E-&LIGB&TX"QQ_ZQO]YB
M,`_[M?1>BZ5;:%HEEI5HNV"TA6)/?`ZGW/4_6ODWPAX:L?$7Q5N=!UNXN+?S
M9KA-T+A6\U23C)!]#0!]3Z;H/AW2-.73["PL(;4+M\L(IW?[Q/+'W->#?&#P
MW;^`_$ND^*_"S1V1EE.Z*$@+'*O.0!_"PR".G!]:[?\`X9[\+_\`03UG_O\`
MI_\`$TC?L\>%7&&U'6&'O,A_]DH`T/B1JD>N?`B[U6(82\M+>8#TW.AQ^'2L
MW]G7_DG]Y_V$'_\`0$K3^).D6^@?`R_TFU:1H+2WABC:0@L0)%ZXK,_9U_Y)
M_>?]A!__`$!*`.$\;WMS\2OC7;>&/.9--M+DVJJIZ!>97_WCM(_`5]%Z9HVF
MZ-IL>G:=90V]HB[1$BC!'OZGW-?-/PZ?[+^T/*EUCS3>WL9)X^?$G^?QKZDH
M`^:_C7X83P5XITOQ1X>7[#]I<LPA^41SK@Y`'0,#TZ<'UKW71-23QEX%M;Y?
MW(U*RPV!G8S*5;'K@Y_*O-?VD98U\)Z1"<>8]Z67UP$.?YBNR^$$#P?"K0ED
MZM$SCZ%V(_0T`9^O_"6#7A:"35Y83!IT>GL4A!\Q$#=>>[%6Q_LUZ%;0_9K6
M&#=N\M%3=ZX&,U+10`5SOB7QII'AB(_:IO-NC]VVB(+GZ_W1[FNBKF]9\!^'
MM<D>6YL1'<.<M-`VQB?4]C^(K.IS\O[O<Z\%]5]JOK5^7R/&/$_CK5_$[M'-
M)]GLLY6VB.%_X$?XC]?RKK_@O:9FU:]/98XE_')/\A2:K\&ID!?2=263_IG<
MKM/_`'T/\*ZOX<>';SPYH5S!J$(BN9+DL0&#94``'(_&O/HT:OMU*H?89GF.
M7O*I4<$TKV5MGOV>O3<K_$+QA/X7N-)%J0SO*TDT9Z/&!C'MG/Z5T]I=:;XI
MT`2Q[9[*[C*LIZ\\%3Z$5XE\4-3_`+0\:W$:G,=HBP#GN.3^I(_"D\`>,G\,
M:GY%RQ;3+E@)1U\L]G']?4?052Q=J\HR^$QEP^YY92K45:JE?UOK;U73[C-\
M2:9J'A37I]/^T7"HIW0R!R-Z'H>/R^H-58?$^O6_^JUF_7V^T-C^=>T_$'PU
M'XH\.+=V6)+NV4RV[)SYJ$9*^^1R/<>]>$V-E-J&H6]E`N9IY%C4>Y.*Y<12
ME2J6CL]CWLIQU',,)SUDN:.DKK\?G_F>Z_#.;5[[P^^HZM>SW'GR8@$ISM1>
M,_B<_D*[6JNFV$6EZ9;6,``B@C$:X]AUJU7LTXN,%%GYMC:\:^(G5BK)O1+3
M3H%9GB3_`)%?5_\`KRF_]`-:=!`(P>15G*>$?LU*RV'B'<I'[V#J/9Z]WIB1
M1Q`B-%3/7:,4^@#,\0Z!I_B?0[G2-3A$EM.N#_>0]F4]B#R*^?/`O@V_\#_'
MS3=+OAOC*3O;S@86:/RGP1[^H[&OI:F-%&TB2,BETSM8CE<]<&@#S'XZ>%;[
MQ)X+BN-.B>:XTZ;SS"@RSQD8;`[D<''H#7(_#7XUZ/HGA:VT/Q%'<P36*F.*
M:*+>KH.@('(8=.F*]_K)N_"_A^_N#<7FAZ;<3'K)-:(['\2*`/"/B?X_O/'G
M@ZX.BZ3/%X>MKB/SKVY7:TTF<*J`9Z=3^'3OZ1\#01\)]+!!!\R?K_UU:O0$
MMH(X%@2&-85X6-4`4?05(J*B[44*OH!@4`<_XX\-Q^+?!VI:.P'F31$PL?X9
M5Y0_F!^!->*?L^>$)'U_4=>OH67^SLVL*N.1,?O_`(@<?\"KZ,IJ1QQ!A&BI
MN)8[1C)/4_6@!U?.WQ<\`ZOH'BL>-_#4<KQM*+B;R5+-;S`Y+8'53U/OG/!K
MZ)HH`\5T']HO1)K%!KVGW=K>*,.;91)&Y]1D@CZ<_6H+[X@:U\5;D^&O!UA<
MV.FS';?ZG,`&2$\,!@X&1VR2>G'->M7/A3PY>3F>YT#2YICUDDM(V8_B16E;
MVUO9PB&V@B@B7HD2!5'X"@#@_BS:I9_!S5+2'<4A@AC3)R<*Z`9_*L/]G92O
MP_O`00?[0?J/]A*]<95=2K*&4]01D4B1I&,(BJ/11B@#Y\^+7@O6?#GC2/QY
MX>@>6+S5N)Q&NXP2KC)(ZE6[_CGJ*[71_CSX-OM*2XU"YEL+L)F6V:%WPW?:
MR@@CTZ&O4.HP:QY_"7ANZG,UQX?TJ64\EWLXV8_B10!\^Z[<:Q\=?&UK#I%G
M/;Z%9?NQ/*/EC4G+.W;<0!A1Z#W-?2&FV%OI6F6NGVB;+>VB6&-?15&!_*I;
M>V@M(5AMH8X8EZ)&H51^`J6@`HHHH`****`"H;JX2SLY[F4XCAC:1CZ`#)J:
MF2Q1S1-%*BO&PPRL,@CT(H8XVNK['SMI_A?7_&.H3WMM:,(YY6D>XE^5`6.3
M@GKU[9KT[P[\*M(TO9/J1_M"Y'.&&(E/^[W_`!_*N]5510J*%4#``&`!2UR4
ML'3AJ]6>_CN(\7B%[.G[D.RW^_\`RL-1$C14155%&%51@`>U<79^`X;+XA2:
M[&$^R-&TB1_W)FX.!Z8R?J:[:BNB5.,K7Z'D4,75H*:INW,K/T844459S!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
$`'__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
